Physician profile
Jayne Bird
NPI 1871887620
$5,411.95
in general payments reported to CMS, 2019-2025
28 companies · $1,653 in 2025
The $1,653 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $50.76 · 2021: $413 · 2022: $419 · 2023: $1,131 · 2024: $1,491 · 2025: $1,653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,274.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,175.41 | 2019-2025 | Rinvoq, Skyrizi |
| Incyte Corporation | $457.77 | 2021-2025 | Opzelura |
| Mayne Pharma Commercial LLC | $370.43 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $364.44 | 2021-2025 | Winlevi, Absorica Ld |
| Janssen Biotech, INC. | $320.80 | 2019-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $313.70 | 2023-2024 | Sotyktu |
| Leo Pharma INC. | $277.55 | 2021-2025 | Adbry, Spevigo |
| Genzyme Corporation | $258.77 | 2021-2025 | |
| Pfizer INC. | $228.34 | 2022-2025 | |
| Allergan, INC. | $218.20 | 2019-2021 | |
| Dermavant Sciences, INC. | $204.32 | 2023-2024 | Vtama |
| Botanix Sb INC | $171.69 | 2025 | Sofdra |
| Arcutis Biotherapeutics, INC. | $146.50 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $144.97 | 2021-2025 | Dupixent |
| Lilly USA, LLC | $141.31 | 2021-2025 | Taltz, Olumiant, Ebglyss |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $131.81 | 2023-2024 | Otezla |
| Organon LLC | $128.84 | 2025 | Vtama, Nexplanon |
| Galderma Laboratories, L.P. | $71.35 | 2023-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $69.87 | 2022-2025 | Cabtreo, Jublia |
| Almirall LLC | $44.51 | 2021-2025 | Klisyri |
| Ucb, INC. | $37.95 | 2025 | Bimzelx |
| Revance Therapeutics, INC. | $34.98 | 2025 | Daxxify |
| Celgene Corporation | $21.83 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.50 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $15.85 | 2021 | |
| Journey Medical Corporation | $14.34 | 2023 | |
| Verrica Pharmaceuticals INC. | $13.92 | 2024 | Ycanth |
| Novartis Pharmaceuticals Corporation | $12.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayne Bird listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.